Amoxicillin by Neopharma Inc / USAntibiotics, LLC AMOXICILLIN capsule

Amoxicillin by

Drug Labeling and Warnings

Amoxicillin by is a Prescription medication manufactured, distributed, or labeled by Neopharma Inc, USAntibiotics, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS & USAGE

    1.1 Infections of the Ear, Nose, and Throat:


    Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY b-lactamase–negative) isolates of Streptococcus species. (a‑ and b‑hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae. 

    1.2 Infections of the Genitourinary Tract:


    Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY b-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis.

    1.3 Infections of the Skin and Skin Structure:


    Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY b-lactamase–negative) isolates of Streptococcus spp. (a‑ and b‑hemolytic isolates only), Staphylococcus spp., or E. coli.

    1.4 Infections of the Lower Respiratory Tract:


    Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY b-lactamase–negative) isolates of Streptococcus spp. (a‑ and b‑hemolytic isolates only), S. pneumoniae,Staphylococcus spp., or H. influenzae.

    1.5 Helicobacter pylori Infection


    Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1‑year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

    Dual therapy for H. pylori with lansoprazole: Amoxicillin, in combination with lansoprazole delayed‑release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1‑year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

    1.6 Usage


    To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

  • 2 DOSAGE & ADMINISTRATION

    2.1 Dosing for Adult and Pediatric Patients > 3 Months of Age


    Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.  It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.  In some infections, therapy may be required for several weeks.  It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.


      Table 1. Dosing Recommendations for Adult and Pediatric Patients > 3 Months of Age



    Infection
    Severitya
    Usual Adult Dose
    Usual Dose for Children > 3 Monthsb

    Ear/Nose/Throat
    Skin/Skin Structure Genitourinary Tract
    Mild/Moderate
    500 mg every 12 hours or 250 mg every 8 hours
    25 mg/kg/day in divided doses every 12 hours
    or
    20 mg/kg/day in divided doses every 8 hours

     
    Severe
    875 mg every 12 hours or 500 mg every 8 hours
    45 mg/kg/day in divided doses every 12 hours
    or
    40 mg/kg/day in divided doses every 8 hours

    Lower Respiratory Tract
    Mild/Moderate or Severe
    875 mg every 12 hours or 500 mg every 8 hours
    45 mg/kg/day in divided doses every 12 hours
    or
    40 mg/kg/day in divided doses every 8 hours

    aDosing for infections caused by bacteria that are intermediate in their susceptibility to amoxicillin should follow the recommendations for severe infections. bThe children’s dosage is intended for individuals whose weight is less than 40 kg. Children weighing 40 kg or more should be dosed according to the adult recommendations.

    2.2 Dosing in Neonates and Infants Aged ≤12 Weeks (≤ 3 Months)


    Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.  It is recommended that there be at least 10 days’ treatment for any infection caused by Streptococcus pyogenes to prevent the occurrence of acute rheumatic fever.  Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of AMOXICILLIN is 30 mg/kg/day divided every 12 hours.  There are currently no dosing recommendations for pediatric patients with impaired renal function.

    2.3 Dosing for H. pylori Infection


    Triple therapy: The recommended adult oral dose is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days.
    Dual therapy: The recommended adult oral dose is 1 gram amoxicillin and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
    Please refer to clarithromycin and lansoprazole full prescribing information.

    2.4 Dosing in Renal Impairment


    Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe.  

    • Severely impaired patients with a glomerular filtration rate of < 30 mL/min. should not receive a 875‑mg dose.
    • Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. 
    • Patients with a glomerular filtration rate less than 10 mL/min should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.
    • Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

      

    2.5 Directions for Mixing Oral Suspension


    Tap bottle until all powder flows freely. Add approximately 1/3 of the total amount of water for reconstitution (see Table 2) and shake vigorously to wet powder. Add remainder of the water and again shake vigorously.


    Table 2. Amount of Water for Mixing Oral Suspension


    Strength
    Bottle Size 
    Amount of Water
    Required for Reconstitution

    Oral Suspension 125 mg/5 mL
    80 mL
    62 mL

     
    100 mL
    78 mL

     
    150 mL
    116 mL

    Oral Suspension 200 mg/5 mL
    50 mL
    39 mL

     
    75 mL
    57 mL

     
    100 mL
    76 mL

    Oral Suspension 250 mg/5 mL
    80 mL
    59 mL

     
    100 mL
    74 mL

     
    150 mL
    111 mL

    Oral Suspension 400 mg/5 mL
    50 mL
    36 mL

     
    75 mL
    54 mL

     
    100 mL
    71 mL


    After reconstitution, the required amount of suspension should be placed directly on the child’s tongue for swallowing. Alternate means of administration are to add the required amount of suspension to formula, milk, fruit juice, water, ginger ale, or cold drinks. These preparations should then be taken immediately.
     
    NOTE: SHAKE ORAL SUSPENSION WELL BEFORE USING. Keep bottle tightly closed. Any unused portion of the reconstituted suspension must be discarded after 14 days. Refrigeration is preferable, but not required.

      

  • 3 DOSAGE FORMS & STRENGTHS


    Capsules: 250 mg,

    500 mg. Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate.  The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500 mg capsule are imprinted with AMOXIL and 500.
    Tablets:  500 mg, 875 mg. Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively.  The 875-mg tablet is scored on the reverse side.
    Powder for Oral Suspension: 125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL. Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gum-flavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate.


  • 4 CONTRAINDICATIONS


    Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or to other b‑lactam antibiotics (e.g., penicillins and cephalosporins). 

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Anaphylactic Reactions


    Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted. 

    5.2 Clostridium difficile Associated Diarrhea


    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    5.3 Development of Drug-Resistant Bacteria


    Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    5.4 Use in Patients With Mononucleosis


    A high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Thus amoxicillin should not be administered to patients with mononucleosis.

    5.5 Phenylketonurics


    Amoxicillin chewable tablets contain aspartame which contains phenylalanine.  Each 200 mg chewable tablet contains 1.82 mg phenylalanine; each 400 mg chewable tablet contains 3.64 mg phenylalanine.  The oral suspensions of Amoxicillin do not contain phenylalanine and can be used by phenylketonurics.

  • 6 ADVERSE REACTIONS


          The following are discussed in more detail in other sections of the labeling:

    ·      Anaphylactic reactions [see Warnings and Precautions (5.1)]

    ·      CDAD [see Warnings and Precautions (5.2)]

    6.1 Clinical Trials Experience


    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most common adverse reactions (> 1%) observed in clinical trials of amoxicillin capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea.

    Triple therapy: The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/ lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%).
    Dual therapy: The most frequently reported adverse events for patients who received double therapy amoxicillin/lansoprazole were diarrhea (8%) and headache (7%). For more information on adverse reactions with clarithromycin or lansoprazole, refer to the Adverse Reactions section of their package inserts.

    6.2 Postmarketing or Other Experience


    In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of penicillins. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to AMOXICILLIN.

    ·      Infections and Infestations: Mucocutaneous candidiasis.
    ·      Gastrointestinal: Black hairy tongue, and hemorrhagic/pseudomembranous colitis.
    Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment [see Warnings and Precautions (5.2)].
    ·      Hypersensitivity Reactions: Anaphylaxis [see Warnings and Precautions (5.1)]. Serum sickness–like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens‑Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria have been reported.
    ·      Liver: A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.
    ·      Renal: Crystalluria has been reported[see Overdosage (10)].

    ·    Hemic and Lymphatic Systems: Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.
    ·      Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported
    ·      Miscellaneous: Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

      

  • 7 DRUG INTERACTIONS

    7.1 Probenecid


    Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.

    7.2 Oral Anticoagulants


    Abnormal prolongation of prothrombin time (increased international normalized ratio [INR]) has been reported in patients receiving amoxicillin and oral anticoagulants.  Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently.  Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.

    7.3 Allopurinol


    The concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

    7.4 Oral Contraceptives


    Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

    7.5 Other Antibacterials


    Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin.  This has been demonstrated in vitro; however, the clinical significance of this interaction is not well documented.

    7.6 Effects on Laboratory Tests


    High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST®, Benedict’s Solution, or Fehling’s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX®) be used.

    Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy


    Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (3 and 6 times the 3 g human dose, based on body surface area). There was no evidence of harm to the fetus due to amoxicillin. There are, however, no adequate and well‑controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, amoxicillin should be used during pregnancy only if clearly needed.

    8.2 Labor & Delivery


    Oral ampicillin is poorly absorbed during labor. It is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood of the necessity for an obstetrical intervention.

    8.3 Nursing Mothers


    Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.

    8.4 Pediatric Use


    Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of AMOXICILLIN should be modified in pediatric patients 12 weeks or younger (£ 3 months). [See Dosage and Administration(2.2).]

    8.5 Geriatric Use


    An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects.  These analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    8.6 Dosing in Renal Impairment


    Amoxicillin is primarily eliminated by the kidney and dosage adjustment is usually required in patients with severe renal impairment (GFR <30 mL/min). See Dosing in Renal Impairment (2.4) for specific recommendations in patients with renal impairment.

  • 10 OVERDOSAGE

    In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms.

    Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin1.

    Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.


    Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.

      

  • 11 DESCRIPTION

    Formulations of AMOXICILLIN contain amoxicillin, a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram‑positive and Gram‑negative microorganisms. Chemically, it is (2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. It may be represented structurally as:


    The amoxicillin molecular formula is C16H19N3O5S·3H2O, and the molecular weight is 419.45.


    Amoxicillin Capsules, USP: Each capsule of AMOXICILLIN, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate.  The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500‑mg capsule are imprinted with AMOXIL and 500. Inactive ingredients: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, magnesium stearate, and titanium dioxide.


    Amoxicillin Tablets, USP:  Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate.  Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively.  The 875-mg tablet is scored on the reverse side.  Inactive ingredients:  Colloidal silicon dioxide, crospovidone, FD&C Red No. 30 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.

      

     Amoxicillin Powder for Oral Suspension, USP: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate. Each 5 mL of the 125-mg reconstituted suspension contains 0.11 mEq (2.51 mg) of sodium.  Each 5 mL of the 200-mg reconstituted suspension contains 0.15 mEq (3.39 mg) of sodium.  Each 5 mL of the 250‑mg reconstituted suspension contains 0.15 mEq (3.36 mg) of sodium; each 5 mL of the 400‑mg reconstituted suspension contains 0.19 mEq (4.33 mg) of sodium. Inactive ingredients: FD&C Red No. 3, flavorings, silica gel, sodium benzoate, sodium citrate, sucrose, and xanthan gum.

      

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action


    Amoxicillin is an antibacterial drug. [see Microbiology (12.4)].

    12.2 Pharmacokinetics


    Absorption: Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of amoxicillin from the tablets and suspension of amoxicillin has been partially investigated; 400‑mg and 875‑mg formulations have been studied only when administered at the start of a light meal. 

    Orally administered doses of 250‑mg and 500‑mg amoxicillin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5.0 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively. 

    Mean amoxicillin pharmacokinetic parameters from an open, two‑part, single‑dose crossover bioequivalence study in 27 adults comparing 875 mg of AMOXICILLIN with 875 mg of AUGMENTIN® (amoxicillin/clavulanate potassium) showed that the 875‑mg tablet of Amoxicillin produces an AUC0-∞ of 35.4 ± 8.1 mcg·hr/mL and a Cmax of 13.8 ± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast.

    Orally administered doses of amoxicillin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3.0 mcg/mL and 3.5 mcg/mL to 5.0 mcg/mL, respectively.


    Oral administration of single doses of 400‑mg chewable tablets and 400 mg/5 mL suspension of amoxicillin to 24 adult volunteers yielded comparable pharmacokinetic data:





    Table 3: Mean Pharmacokinetic Parameters of Amoxicillin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults





    Dose
    AUC0-∞ (mcg·hr/mL)

    Cmax (mcg/mL)†

    Amoxicillin
    Amoxicillin (±S.D.)
    Amoxicillin (±S.D.)

    400 mg (5 mL of suspension)
    17.1 (3.1)
    5.92 (1.62)

    400 mg (1 chewable tablet)
    17.1 (3.1)
    5.18 (1.64)

    * Administered at the start of a light meal.
    † Mean values of 24 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.


    Distribution: Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, amoxicillin is approximately 20% protein‑bound. Following a 1‑gram dose and utilizing a special skin window technique to determine levels of the antibiotic, it was noted that therapeutic levels were found in the interstitial fluid.
               
    Metabolism and Excretion: The half-life of amoxicillin is 61.3 minutes. Approximately 60% of an orally administered dose of amoxicillin is excreted in the urine within 6 to 8 hours.  Detectable serum levels are observed up to 8 hours after an orally administered dose of amoxicillin. Since most of the amoxicillin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid [see DRUG INTERACTIONS (7.1)].

      

    12.4 Microbiology


    Mechanism of Action
    Amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication.  It acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria.

    Mechanism of Resistance
    Resistance to amoxicillin is mediated primarily through enzymes called beta-lactamases that cleave the beta-lactam ring of amoxicillin, rendering it inactive.

    Amoxicillin has been shown to be active against most isolates of the bacteria listed below, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.


    Gram-Positive Bacteria
    Enterococcus faecalis
    Staphylococcus spp.
    Streptococcus pneumoniae
    Streptococcus spp. (alpha and beta-hemolytic)
    Gram-Negative Bacteria
    Escherichiacoli
    Haemophilus influenzae 
    Helicobacter pylori 
    Proteus mirabilis 

       Susceptibility Test Methods:
     For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility


    Long‑term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate (AUGMENTIN). Augmentin was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. Augmentin was weakly positive in the mouse lymphoma assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival. Augmentin was negative in the mouse micronucleus test and in the dominant lethal assay in mice. Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays. In a multi‑generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 2 times the 3 g human dose based on body surface area).

  • 14 CLINICAL STUDIES

    14.1 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence


     Randomized, double-blind clinical studies performed in the United States in patients with H. pylori and duodenal ulcer disease   (defined as an active ulcer or history of an ulcer within 1 year) evaluated the efficacy of lansoprazole in combination with amoxicillin capsules and clarithromycin tablets as triple 14‑day therapy, or in combination with amoxicillin capsules as dual 14‑day therapy, for the eradication of H. pylori. Based on the results of these studies, the safety and efficacy of 2 different eradication regimens were established:  Triple therapy: Amoxicillin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg twice daily (see Table 6).  Dual therapy: Amoxicillin 1 gram three times daily/lansoprazole 30 mg three times daily (see Table 7).  All treatments were for 14 days. H. pylori eradication was defined as 2 negative tests (culture and histology) at 4 to 6 weeks following the end of treatment.  Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.


    Table 6. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Triple Therapy Regimen


    Study
    Triple Therapy
    Triple Therapy

    Evaluable Analysisa
    [95% Confidence Interval]
    (number of patients)
    Intent-to-Treat Analysisb
    [95% Confidence Interval]
    (number of patients)

    Study 1
    92
    [80.0 ‑ 97.7]
    (n = 48)
    86
    [73.3 ‑ 93.5]
    (n = 55)

    Study 2
    86
    [75.7 ‑ 93.6]
    (n = 66)
    83
    [72.0 ‑ 90.8]
    (n = 70)

    a     This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest®, histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.
    b    Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.
     
    Table 7. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Dual Therapy Regimen  


    Study
    Dual Therapy
    Dual Therapy

    Evaluable Analysisa
    [95% Confidence Interval]
    (number of patients)
    Intent-to-Treat Analysisb
    [95% Confidence Interval]
    (number of patients)

    Study 1
    77
    [62.5 ‑ 87.2]
    (n = 51)
    70
    [56.8 ‑ 81.2]
    (n = 60)

    Study 2
    66
    [51.9 ‑ 77.5]
    (n = 58)
    61
    [48.5 ‑ 72.9]
    (n = 67)

    a     This analysis was based on evaluable patients with confirmed duodenal ulcer (active or within 1 year) and H. pylori infection at baseline defined as at least 2 of 3 positive endoscopic tests from CLOtest®, histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.
    b     Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within 1 year). All dropouts were included as failures of therapy.


      

  • 15 REFERENCES


    1.      Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66‑67.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING


    Amoxicillin Capsules, USP: Each capsule of amoxicillin, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg amoxicillin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500 mg capsule are imprinted with AMOXIL and 500.

    250-mg Capsule
    NDC: 72508-225-01          Bottles of 100


    NDC: 72508-225-05          Bottles of 500



    500-mg Capsule
    NDC: 72508-205-01          Bottles of 100
    NDC: 72508-205-05          Bottles of 500
     
    Amoxicillin Tablets, USP:  Each tablet contains 500 mg or 875 mg amoxicillin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively.  The 875-mg tablet is scored on the reverse side.
     
    500-mg Tablet
    NDC: 72508-224-14          Bottles of 20
    NDC: 72508-224-01          Bottles of 100
    NDC: 72508-224-05          Bottles of 500
     
    875-mg Tablet
    NDC: 72508-219-14          Bottles of 20
    NDC: 72508-219-01          Bottles of 100
     
    Amoxicillin Powder for Oral Suspension, USP: Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg amoxicillin as the trihydrate. Each 5 mL of reconstituted bubble-gum-flavored suspension contains 200 mg, 250 mg or 400 mg amoxicillin as the trihydrate.

    125 mg/5 mL
    NDC: 72508-222-80          80-mL bottle
    NDC: 72508-222-52          100-mL bottle
    NDC: 72508-222-53          150-mL bottle
               
    200 mg/5 mL 
    NDC: 72508-223-50          50-mL bottle
    NDC: 72508-223-51          75-mL bottle
    NDC: 72508-223-52          100-mL bottle
               
    250 mg/5 mL
    NDC: 72508-209-80          80-mL bottle
    NDC: 72508-209-52          100-mL bottle                                    
    NDC: 72508-209-53          150-mL bottle
     
    400 mg/5 mL
    NDC: 72508-207-50          50-mL bottle
    NDC: 72508-207-51          75-mL bottle
    NDC: 72508-207-52          100-mL bottle
     
    Store at 20°C – 25°C (68°F – 77°F) [See USP Controlled Room Temperature].
    Dispense in a tight container as defined in the USP
    Keep this and all drugs out of the reach of children.

  • 17 PATIENT COUNSELING INFORMATION


    Information for Patients


    • Patients should be advised that amoxicillin may be taken every 8 hours or every 12 hours, depending on the dose prescribed.
    • Patients should be counseled that antibacterial drugs, including amoxicillin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When amoxicillin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin or other antibacterial drugs in the future.
    • Patients should be counseled that diarrhea is a common problem caused by antibiotics, and it usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken their last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
    • Patients should be aware that amoxicillin contains a penicillin class drug product that can cause allergic reactions in some individual

      
    CLINITEST is a registered trademark of Miles, Inc.
    CLINISTIX is a registered trademark of Bayer Corporation.
    CLOtest is a registered trademark of Kimberly-Clark Corporation.

    AMOXIL is registered trademark of GlaxoSmithKline and is licensed to Neopharma Inc.
     
    Manufactured By:
    Neopharma Tennessee LLC.
    Bristol, TN 37620

    Manufactured for:
    Neopharma Inc.
    Princeton, NJ 08540

    Revised: 09/2019


  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Amoxicillin Capsules USP 250 mg- 100 ct 
    NDC: 72508-225-01



    250 mg- 100 ct

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Amoxicillin Capsules USP 250 mg- 500 ct 
    NDC: 72508-225-05



    250 mg- 500 ct
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Amoxicillin Capsules USP 500 mg- 100 ct 
    NDC: 72508-205-01



    500 mg- 100 ct
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Amoxicillin Capsules USP 500 mg- 500 ct 
    NDC: 72508-205-05



    500 mg- 500 ct
  • INGREDIENTS AND APPEARANCE
    AMOXICILLIN 
    amoxicillin capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72508-225
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9) AMOXICILLIN ANHYDROUS250 mg
    Inactive Ingredients
    Ingredient NameStrength
    D&C RED NO. 28 (UNII: 767IP0Y5NH)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    GELATIN (UNII: 2G86QN327L)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorBLUE (opaque cap) , PINK (opaque cap) Scoreno score
    ShapeCAPSULESize19mm
    FlavorImprint Code AMOXILand250
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72508-225-01100 in 1 BOTTLE; Type 0: Not a Combination Product04/03/2019
    2NDC: 72508-225-05500 in 1 BOTTLE; Type 0: Not a Combination Product04/03/2019
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06221604/03/2019
    AMOXICILLIN 
    amoxicillin capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72508-205
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    AMOXICILLIN (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9) AMOXICILLIN ANHYDROUS500 mg
    Inactive Ingredients
    Ingredient NameStrength
    D&C RED NO. 28 (UNII: 767IP0Y5NH)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    GELATIN (UNII: 2G86QN327L)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    Product Characteristics
    ColorBLUE (opaque cap) , PINK (opaque body) Scoreno score
    ShapeCAPSULESize23mm
    FlavorImprint Code Amoxil500
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72508-205-01100 in 1 BOTTLE; Type 0: Not a Combination Product04/03/2019
    2NDC: 72508-205-05500 in 1 BOTTLE; Type 0: Not a Combination Product04/03/2019
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06221604/03/2019
    Labeler - Neopharma Inc (081234828)
    Establishment
    NameAddressID/FEIBusiness Operations
    Neopharma Tennessee LLC967940441ANALYSIS(72508-205, 72508-225) , MANUFACTURE(72508-205, 72508-225) , PACK(72508-205, 72508-225)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.